drugset
drugset / Trial / NCT02824354

Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.

NCT02824354 ↗

Phase 3 Withdrawn Centre Hospitalier Universitaire, Amiens
RandomizedParallel-groupDouble-blindTreatment

Summary

Nalmefene is the first drug to obtain Marketing Authorisation in France for reduction of alcohol consumption.

Timeline

Start
2018-12-01
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 18 mg —

Indications

alcohol dependence cirrhosis of liver